Tous Actualités
Suivre
Abonner Epigenomics AG

Epigenomics AG

EANS-News: Epigenomics Signs Distribution Deal with DPC for Epi proColon in Middle East

BERLIN and SEATTLE, November 5, 2010 (euro adhoc) -

Third distribution agreement for Epi proColon completes the picture 
for the Middle East
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
Company Information/Molecular diagnostics
Subtitle: Third distribution agreement for Epi proColon completes the
picture for the Middle East
Epigenomics AG
(Frankfurt Prime Standard: ECX), the cancer diagnostics company, 
today announced that the company has signed an exclusive distributor 
agreement with DPC LEBANON for the commercialization of Epigenomics´ 
Epi proColon test in Lebanon, United Arab Emirates, Saudi Arabia, 
Qatar, Kuwait, Syria, Jordan and Egypt.
Epi proColon is the world´s first CE-marked molecular diagnostic test
for the early detection of colorectal cancer in blood. The test uses 
Epigenomics´ proprietary colorectal cancer biomarker Septin9 in blood
plasma. DPC expects to begin marketing the test in the next few 
weeks.
Colorectal cancer is the third leading cause of cancer-related death 
in the Western world and is also major threat to public health 
throughout the Middle East. The disease is highly curable when 
detected at an early still localized stage.  Survival chances, 
however, diminish once the tumor has spread to distant organs and the
disease has become obvious with patients showing symptoms.
"We are delighted to be commercializing Epi proColon in Lebanon and 
throughout the Middle East," Leila Macaron, General Manager of DPC 
commented. "Early detection of colorectal cancer is critical to the 
effective treatment of this disease and we believe that this blood 
test is a simple procedure that can be easily incorporated into 
clinical regimes and screening programs."
"Signing this deal with DPC completes the picture for the Middle East
following our recent deals in Turkey and Israel," commented Geert 
Nygaard, Chief Executive Officer of Epigenomics. "DPC will join 
DATEKS and Pronto as important partners in our continuously growing 
distributor network for our Epi proColon product"
Epi proColon is currently marketed by Epigenomics directly in 
Germany, Austria and Switzerland. Outside this home market, it is 
Epigenomics´ strategy to make the CE-marked test broadly available 
through a mix of direct commercialization and a distributor network.
-Ends-
Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 368 
pr@epigenomics.com
www.epigenomics.com
About Epigenomics
Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation 
biomarkers, Epigenomics´ tests on the market and in development for 
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially 
increasing the patient´s chances of survival.
For development and global commercialization of IVD test products, 
Epigenomics pursues a dual business strategy in which direct 
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with 
broad customer access. Strategic diagnostics industry partners 
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics 
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc. 
for diagnostics test products and services, and QIAGEN N.V. for 
sample preparation solutions and research products.
The company is headquartered in Berlin, Germany, and has a wholly 
owned subsidiary, Epigenomics Inc., in Seattle, WA, USA. For more 
information, please visit Epigenomics´ website at 
www.epigenomics.com.
Notes for editors
Epi proColon
Epi proColon, developed by Epigenomics, is a CE-marked test kit for 
the detection of methylated DNA of the Septin9 gene in blood plasma. 
This Septin9 biomarker has been shown in numerous clinical studies to
be closely associated with the presence of colorectal cancer and may 
aid in the detection of this common cancer. Septin9 is one of the 
best and most systematically validated biomarkers for the early 
detection of colorectal cancer today. In particular, the recent 
PRESEPT Study was a successful prospective evaluation of Epi proColon
detection of methylated Septin9 in a cohort of about 8,000 
individuals representative of a typical screening population.
Epigenomics´ legal disclaimers. This communication expressly or 
implicitly contains certain forward-looking statements concerning 
Epigenomics AG and its business. Such statements involve certain 
known and unknown risks, uncertainties and other factors which could 
cause the actual results, financial condition, performance or 
achievements of Epigenomics AG to be materially different from any 
future results, performance or achievements expressed or implied by 
such forward-looking statements. Epigenomics AG is providing this 
communication as of this date and does not undertake to update any 
forward- looking statements contained herein as a result of new 
information, future events or otherwise.
The information contained in this communication does not constitute 
nor imply an offer to sell or transfer any product, and no product 
based on this technology is currently available for sale by 
Epigenomics in the United States of America. The analytical and 
clinical performance characteristics of any product based on this 
technology which may be sold at some future time in the USA have not 
been established.
end of announcement                               euro adhoc

Further inquiry note:

Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Tel: +49 30 24345 368
achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade

Plus de actualités: Epigenomics AG
Plus de actualités: Epigenomics AG